Study of Pembrolizumab with BEAM Conditioning and Autologous Stem Cell Transplant Followed by Pembrolizumab Maintenance for Relapsed or Refractory Classic Hodgkin Lymphoma

What this Trial Is About

Researchers are evaluating the efficacy and safety of Pembrolizumab combined with the BEAM conditioning regimen before autologous stem cell transplant ASCT for patients with relapsed or refractory classic Hodgkin lymphoma. This Phase 2 single-arm study aims to assess progression-free survival and overall survival following this treatment approach. Participants receive 200 mg of Pembrolizumab intravenously starting 28 days before the stem cell transplant and again on day -6. The BEAM conditioning regimen includes Carmustine, Etoposide, Cytarabine, and Melphalan administered on specified days before the transplant. After the stem cell transplant on day 0, Pembrolizumab infusions resume at day 30 and continue every 3 weeks for one year as maintenance therapy. During the study, participants will be monitored through clinical assessments, laboratory tests, and imaging to evaluate progression-free survival up to one year post-transplant and overall survival up to five years post-transplant. Safety and radiologic response rates will also be tracked at specified time points. The total participation period includes treatment administration and long-term follow-up for outcomes.

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma